Yes, some individuals with moderate to severe rheumatoid arthritis have switched from Humira (adalimumab) to Hyrimoz (adalimumab-adaz), which is a biosimilar to Humira. Hyrimoz is used as targeted therapy for rheumatoid arthritis and works by blocking the activity of tumor necrosis factor (TNF), a substance that can cause Show Full Answer

Yes, some individuals with moderate to severe rheumatoid arthritis have switched from Humira (adalimumab) to Hyrimoz (adalimumab-adaz), which is a biosimilar to Humira. Hyrimoz is used as targeted therapy for rheumatoid arthritis and works by blocking the activity of tumor necrosis factor (TNF), a substance that can cause inflammation and contribute to the symptoms of rheumatoid arthritis. It's taken every other week via subcutaneous injection. People might consider switching to a biosimilar like Hyrimoz for various reasons, including cost considerations or insurance coverage changes. It's important to discuss any potential switch with a healthcare provider, considering factors like efficacy, safety, and how the body might respond to a different formulation.

 This AI-generated response comes from myRAteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Interchangeability study of Humira biosimilar enrolls first patient – CreakyJoints

Hyrimoz (Adalimumab-adaz) for Rheumatoid Arthritis | myRAteam